*Following previous approvals in the EU and Japan, the FDA finally gave BIMZELX® green light for the treatment of moderate-severe plaque psoriasis in the US. The drug will be available from next month onwards.*UCB guides for BIMZELX® global peak sales of EUR 4bn while we currently project BIMZELX® peak sales of close to EUR 3bn with 50% stemming from psoriasis (of which 60% US sales), while still excluding hidradenitis suppurativa. Hence our estimate might still be somewhat conservative. We consider BIMZELX® as a best-in-class anti-IL17 efficacy-wise but highlight the suicidal ideation among other factors in the drug label which could